A detailed history of Virtus ETF Advisers LLC transactions in Bei Gene, Ltd. stock. As of the latest transaction made, Virtus ETF Advisers LLC holds 1,979 shares of BGNE stock, worth $371,062. This represents 0.22% of its overall portfolio holdings.

Number of Shares
1,979
Previous 1,979 -0.0%
Holding current value
$371,062
Previous $282,000 57.45%
% of portfolio
0.22%
Previous 0.14%

Shares

28 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

SELL
$129.52 - $174.32 $6,735 - $9,064
-52 Reduced 2.56%
1,979 $282,000
Q1 2024

May 15, 2024

BUY
$141.8 - $181.47 $41,405 - $52,989
292 Added 16.79%
2,031 $317,000
Q4 2023

Feb 15, 2024

BUY
$158.67 - $201.58 $44,427 - $56,442
280 Added 19.19%
1,739 $313,000
Q3 2023

Nov 07, 2023

SELL
$179.87 - $225.13 $34,535 - $43,224
-192 Reduced 11.63%
1,459 $262,000
Q2 2023

Aug 14, 2023

BUY
$178.3 - $266.78 $31,915 - $47,753
179 Added 12.16%
1,651 $294,000
Q1 2023

May 15, 2023

BUY
$215.53 - $274.5 $5,603 - $7,137
26 Added 1.8%
1,472 $317,000
Q4 2022

Feb 14, 2023

SELL
$125.51 - $229.3 $42,045 - $76,815
-335 Reduced 18.81%
1,446 $318,000
Q3 2022

Nov 14, 2022

BUY
$131.8 - $202.24 $3,031 - $4,651
23 Added 1.31%
1,781 $240,000
Q2 2022

Aug 12, 2022

BUY
$121.11 - $216.05 $51,108 - $91,173
422 Added 31.59%
1,758 $285,000
Q4 2021

Feb 14, 2022

BUY
$248.56 - $389.34 $1,988 - $3,114
8 Added 0.6%
1,336 $362,000
Q3 2021

Nov 15, 2021

SELL
$249.6 - $403.14 $29,952 - $48,376
-120 Reduced 8.29%
1,328 $482,000
Q2 2021

Aug 10, 2021

SELL
$292.75 - $367.01 $377,940 - $473,809
-1,291 Reduced 47.13%
1,448 $497,000
Q1 2021

May 17, 2021

BUY
$260.64 - $382.12 $18,244 - $26,748
70 Added 2.62%
2,739 $953,000
Q4 2020

Feb 12, 2021

SELL
$221.31 - $316.61 $198,293 - $283,682
-896 Reduced 25.13%
2,669 $690,000
Q3 2020

Nov 13, 2020

BUY
$189.18 - $286.44 $56,754 - $85,932
300 Added 9.19%
3,565 $1.02 Million
Q2 2020

Aug 05, 2020

SELL
$123.9 - $195.41 $9,664 - $15,241
-78 Reduced 2.33%
3,265 $615,000
Q1 2020

May 14, 2020

SELL
$121.84 - $173.19 $34,358 - $48,839
-282 Reduced 7.78%
3,343 $412,000
Q4 2019

Feb 13, 2020

BUY
$115.78 - $208.34 $170,196 - $306,259
1,470 Added 68.21%
3,625 $601,000
Q3 2019

Nov 12, 2019

SELL
$120.61 - $148.29 $14,473 - $17,794
-120 Reduced 5.27%
2,155 $264,000
Q2 2019

Aug 13, 2019

BUY
$113.99 - $146.86 $26,673 - $34,365
234 Added 11.46%
2,275 $282,000
Q1 2019

May 14, 2019

SELL
$122.82 - $151.83 $25,669 - $31,732
-209 Reduced 9.29%
2,041 $269,000
Q4 2018

Feb 05, 2019

SELL
$107.01 - $175.15 $42,696 - $69,884
-399 Reduced 15.06%
2,250 $316,000
Q3 2018

Nov 14, 2018

SELL
$152.62 - $189.66 $295,777 - $367,561
-1,938 Reduced 42.25%
2,649 $456,000
Q2 2018

Aug 10, 2018

SELL
$152.5 - $216.77 $532,987 - $757,611
-3,495 Reduced 43.24%
4,587 $705,000
Q1 2018

May 14, 2018

BUY
$97.41 - $177.22 $423,636 - $770,729
4,349 Added 116.5%
8,082 $1.36 Million
Q4 2017

Feb 14, 2018

SELL
$79.6 - $114.73 $348,648 - $502,517
-4,380 Reduced 53.99%
3,733 $365,000
Q3 2017

Nov 14, 2017

BUY
$66.19 - $103.46 $37,066 - $57,937
560 Added 7.41%
8,113 $839,000
Q2 2017

Aug 14, 2017

BUY
N/A
7,553
7,553 $340,000

Others Institutions Holding BGNE

About BeiGene, Ltd.


  • Ticker BGNE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 103,700,000
  • Market Cap $19.4B
  • Description
  • BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplas...
More about BGNE
Track This Portfolio

Track Virtus ETF Advisers LLC Portfolio

Follow Virtus ETF Advisers LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Virtus ETF Advisers LLC, based on Form 13F filings with the SEC.

News

Stay updated on Virtus ETF Advisers LLC with notifications on news.